Advances in G protein-coupled receptor allostery: From function to structure

Molecular Pharmacology

Volumn 86, Issue 5, 2014, Pages 463-478

  Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; RECEPTOR SUBTYPE; LIGAND;

ALLOSTERISM; AMINO ACID SEQUENCE; BINDING AFFINITY; BINDING SITE; DRUG SELECTIVITY; HUMAN; LIGAND BINDING; PHARMACOPHORE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DEVELOPMENT; METABOLISM; PHYSIOLOGY; PROCEDURES;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907575186     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.094342     Document Type: Review

References (191)

1. Abdul-Ridha A, Lane JR, Sexton PM, Canals M, and Christopoulos A (2013) Allosteric modulation of a chemogenetically modified G protein-coupled receptor. Mol Pharmacol 83:521-530.
2. Abdul-Ridha A, López L, Keov P, Thal DM, Mistry SN, Sexton PM, Lane JR, Canals M, and Christopoulos A (2014) Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor. J Biol Chem 289:6067-6079.
3. Ahn KH, Mahmoud MM, and Kendall DA (2012) Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem 287:12070-12082.
4. Allison M (2012) Reinventing clinical trials. Nat Biotechnol 30:41-49.
5. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, and Bertoni S et al. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23:442-450.
6. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
7. Avlani VA, Langmead CJ, Guida E, Wood MD, Tehan BG, Herdon HJ, Watson JM, Sexton PM, and Christopoulos A (2010) Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol Pharmacol 78:94-104.
8. Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, and Gertsch J (2012) Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem 287:36944-36967.
9. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
10. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, and Messa P et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525.
11. Bock A, Merten N, Schrage R, Dallanoce C, Bätz J, Klöckner J, Schmitz J, Matera C, Simon K, and Kebig A et al. (2012) The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 3:1044.
12. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, and Paul SM (1997) The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 11 (Suppl 4):S16-S22.
13. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, and Bianciotto M et al. (2013) Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 23:477-488.
14. Borda E, Camusso JJ, Perez Leiros C, Bacman S, Hubscher O, Arana R, and Sterin-Borda L (1996) Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren's syndrome. Mol Cell Biochem 163-164: 335-341.
15. Bradley SJ, Langmead CJ, Watson JM, and Challiss RA (2011) Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol 79:874-885.
16. Braestrup C, Nielsen M, Krogsgaard-Larsen P, and Falch E (1979) Partial agonists for brain GABA/benzodiazepine receptor complex. Nature 280:331-333.
17. Broadhead GK, Mun HC, Avlani VA, Jourdon O, Church WB, Christopoulos A, Delbridge L, and Conigrave AD (2011) Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids. J Biol Chem 286:8786-8797.
18. Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
19. Busque SM, Kerstetter JE, Geibel JP, and Insogna K (2005) L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells. Am J Physiol Gastrointest Liver Physiol 289:G664-G669.
20. Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, and Christopoulos A (2012) A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem 287:650-659.
21. Canals M, Sexton PM, and Christopoulos A (2011) Allostery in GPCRs: 'MWC' revisited. Trends Biochem Sci 36:663-672.
22. Catterall WA, Cestèle S, Yarov-Yarovoy V, Yu FH, Konoki K, and Scheuer T (2007) Voltage-gated ion channels and gating modifier toxins. Toxicon 49:124-141.
23. Chan WY,McKinzie DL, Bose S, Mitchell SN,Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, and Bymaster FP et al. (2008) Allosteric modulation of the muscarinicM4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
24. Changeux JP (2013) 50 years of allosteric interactions: the twists and turns of the models. Nat Rev Mol Cell Biol 14:819-829.
25. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, and Kobilka BK et al. (2007) High-resolution crystal structure of an engineered human b2-adrenergic G protein-coupled receptor. Science 318:1258-1265.
26. Christopoulos A (2000) Overview of receptor allosterism, in Current Protocols in Pharmacology (Enna SJ ed) pp 1.21.21-21.21.45, Wiley and Sons, New York.
27. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
28. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, and Pin JP et al. (2014) International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol Rev 66:918-947.
29. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, and Sexton PM (2003) Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 278:3293-3297.
30. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
31. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, and Sexton PM (1999) Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56:235-242.
32. Clark AL and Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58:323-331.
33. Ciolek J, Maïga A, Marcon E, Servent D, and Gilles N (2011) Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor. Eur J Pharmacol 655:1-8.
34. Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
35. Conigrave AD and Hampson DR (2010) Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development. Pharmacol Ther 127:252-260.
36. Conigrave AD, Quinn SJ, and Brown EM (2000) L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci USA 97:4814-4819.
37. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
38. Coureuil M, Lécuyer H, Scott MG, Boularan C, Enslen H, Soyer M, Mikaty G, Bourdoulous S, Nassif X, and Marullo S (2010) Meningococcus hijacks a β2-adrenoceptor/β-arrestin pathway to cross brain microvasculature endothelium. Cell 143:1149-1160.
39. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, and Christopoulos A (2012) Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology 153:1232-1241.
40. De Lean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled betaadrenergic receptor. J Biol Chem 255:7108-7117.
41. De Smet F, Christopoulos A, and Carmeliet P (2014) Allosteric targeting of receptor tyrosine kinases. Nat Biotechnol, in press.
42. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K, Mohr K, De Amici M, and Holzgrabe U (2006) Design, synthesis, and action of oxotremorinerelated hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 49:366-372.
43. Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, Arlow DH, Canals M, Lane JR, and Rahmani R et al. (2013) Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503:295-299.
44. Ehlert FJ (1985) The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol Pharmacol 28:410-421.
45. Ehlert FJ, Ragan P, Chen A, Roeske WR, and Yamamura HI (1982) Modulation of benzodiazepine receptor binding: insight into pharmacological efficacy. Eur J Pharmacol 78:249-253.
46. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754.
47. Ellis J and Seidenberg M (1992) Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641.
48. Eroglu C, Brugger B, Wieland F, and Sinning I (2003) Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts. Proc Natl Acad Sci USA 100:10219-10224.
49. Estébanez-Perpiñá E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, and Guy RK et al. (2007) A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 104:16074-16079.
50. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A, and Summers RJ (2011) Quantification of functional selectivity at the human a(1A)-adrenoceptor. Mol Pharmacol 79:298-307.
51. Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, Cherezov V, Roth BL, and Stevens RC (2014) Molecular control of d-opioid receptor signalling. Nature 506:191-196.
52. Fenton AW (2008) Allostery: an illustrated definition for the 'second secret of life'. Trends Biochem Sci 33:420-425.
53. Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP, and Guitart X (2014) G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 66:413-434.
54. Figueroa KW, Griffin MT, and Ehlert FJ (2009) Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 328: 331-342.
55. Fillion G, Rousselle JC, Massot O, Zifa E, Fillion MP, and Prudhomme N (1996) A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors. Behav Brain Res 73:313-317.
56. Galvez T, Urwyler S, Prézeau L, Mosbacher J, Joly C, Malitschek B, Heid J, Brabet I, Froestl W, and Bettler B et al. (2000) Ca(2+) requirement for high-affinity gammaaminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol Pharmacol 57:419-426.
57. Gimpl G, Burger K, and Fahrenholz F (1997) Cholesterol as modulator of receptor function. Biochemistry 36:10959-10974.
58. Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Pétrin D, Le Gouill C, Devost D, Zingg HH, and Bouvier M et al. (2010) A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2a-mediated Rho/ ROCK signaling pathway. J Biol Chem 285:25624-25636.
59. Grazzini E, Guillon G, Mouillac B, and Zingg HH (1998) Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392:509-512.
60. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285: 7459-7474.
61. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, and Felts AS et al. (2012) Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol Pharmacol 82:860-875.
62. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, and Onorato JJ (1997) Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272:28849-28852.
63. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, and Haga T et al. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547-551.
64. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, and Stevens RC (2008) A specific cholesterol binding site is established by the 2.8 Å structure of the human b2-adrenergic receptor. Structure 16:897-905.
65. Hay DL, Poyner DR, and Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 109:173-197.
66. Hedlund PB, Carson MJ, Sutcliffe JG, and Thomas EA (1999) Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol 58:1807-1813.
67. Hernández CC, Barcellos LC, Giménez LE, Cabarcas RA, Garcia S, Pedrosa RC, Nascimento JH, Kurtenbach E, Masuda MO, and Campos de Carvalho AC (2003) Human chagasic IgGs bind to cardiac muscarinic receptors and impair L-type Ca2+ currents. Cardiovasc Res 58:55-65.
68. Hollenstein K, Kean J, Bortolato A, Cheng RK, Doré AS, Jazayeri A, Cooke RM, Weir M, and Marshall FH (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438-443.
69. Holst B, Elling CE, and Schwartz TW (2002) Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors. J Biol Chem 277: 47662-47670.
70. Hughes TS, Giri PK, de Vera IM, Marciano DP, Kuruvilla DS, Shin Y, Blayo AL, Kamenecka TM, Burris TP, and Griffin PR et al. (2014) An alternate binding site for PPARg ligands. Nat Commun 5:3571.
71. Huynh T, Valant C, Crosby IT, Sexton PM, Christopoulos A, and Capuano B (2013) Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. J Med Chem 56:8196-8200.
72. Jacobson MA, Kreatsoulas C, Pascarella DM, O'Brien JA, and Sur C (2010) The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. Mol Pharmacol 78:648-657.
73. Jacoby DB, Gleich GJ, and Fryer AD (1993) Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 91:1314-1318.
74. Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, and Stevens RC (2014) Allosteric sodium in class A GPCR signaling. Trends Biochem Sci 39:233-244.
75. Kebig A, Kostenis E, Mohr K, and Mohr-Andrä M (2009) An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators. J Recept Signal Transduct Res 29:140-145.
76. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
77. Kenakin T and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205-216.
78. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
79. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
80. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
81. Keov P, Valant C, Devine SM, Lane JR, Scammells PJ, Sexton PM, and Christopoulos A (2013) Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M1 muscarinic acetylcholine receptor. Mol Pharmacol 84:425-437.
82. Kerr DI and Ong J (2003) Potentiation of metabotropic GABAB receptors by L-amino acids and dipeptides in rat neocortex. Eur J Pharmacol 468:103-108.
83. Koole C, Wootten D, Simms J, Savage EE, Miller LJ, Christopoulos A, and Sexton PM (2012) Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J Biol Chem 287:3659-3673.
84. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456-465.
85. Koshland DE, Jr, Némethy G, and Filmer D (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5:365-385.
86. Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, and Wess J (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13:549-560.
87. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, and Sexton PM et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101-106.
88. Lagerström MC and Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357.
89. Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, Lopez L, Scammells PJ, and Capuano B et al. (2014) A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol, in press.
90. Lane JR, Sexton PM, and Christopoulos A (2013) Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 34:59-66.
91. Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VA, Hagan JJ, and Herdon HJ et al. (2008) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 154:1104-1115.
92. Langmead CJ and Christopoulos A (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 27:475-481.
93. Langmead CJ and Christopoulos A (2014) Functional and structural perspectives on allosteric modulation of GPCRs. Curr Opin Cell Biol 27:94-101.
94. Lazareno S, Dolezal V, Popham A, and Birdsall NJM (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol 65:257-266.
95. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, and Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855-869.
96. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389.
97. Leach K, Simms J, Sexton PM, and Christopoulos A (2012) Structure-function studies of muscarinic acetylcholine receptors. Handb Exp Pharmacol 208:29-48.
98. Leach K, Wen A, Cook AE, Sexton PM, Conigrave AD, and Christopoulos A (2013) Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. Endocrinology 154:1105-1116.
99. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, and Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253-262.
100. Leiros CP, Sterin-Borda L, Borda ES, Goin JC, and Hosey MM (1997) Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease. J Biol Chem 272:12989-12993.
101. Liou AP, Sei Y, Zhao X, Feng J, Lu X, Thomas C, Pechhold S, Raybould HE, and Wank SA (2011) The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells. Am J Physiol Gastrointest Liver Physiol 300:G538-G546.
102. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
103. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, and IJzerman AP et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-236.
104. Lüllmann H, Ohnesorge FK, Schauwecker G-C, and Wassermann O (1969) Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkanebis-ammonium compounds. Eur J Pharmacol 6:241-247.
105. Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, and Pearson M et al. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 106:15950-15955.
106. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, and Galzi JL (2007) A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 21: 2124-2134.
107. Makita N, Sato J, Manaka K, Shoji Y, Oishi A, Hashimoto M, Fujita T, and Iiri T (2007) An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. Proc Natl Acad Sci USA 104:5443-5448.
108. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, and Luo Q et al. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75:577-588.
109. Mary S, Damian M, Louet M, Floquet N, Fehrentz JA, Marie J, Martinez J, and Banères JL (2012) Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci USA 109: 8304-8309.
110. Massot O, Rousselle JC, Fillion MP, Grimaldi B, Cloëz-Tayarani I, Fugelli A, Prudhomme N, Seguin L, Rousseau B, and Plantefol M et al. (1996) 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. Mol Pharmacol 50: 752-762.
111. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, and Kostenis E (2005) Identification of indole derivatives exclusively interfering with a G proteinindependent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol 68:393-402.
112. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
113. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339.
114. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, and Lindsley CW (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55:1445-1464.
115. Mistry SN, Valant C, Sexton PM, Capuano B, Christopoulos A, and Scammells PJ (2013) Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. J Med Chem 56:5151-5172.
116. Mohr K, Schmitz J, Schrage R, Tränkle C, and Holzgrabe U (2013) Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl 52:508-516.
117. Mohr K, Tränkle C, Kostenis E, Barocelli E, De Amici M, and Holzgrabe U (2010) Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 159:997-1008.
118. Monod J, Changeux J-P, and Jacob F (1963) Allosteric proteins and cellular control systems. J Mol Biol 6:306-329.
119. Monod J, Wyman J, and Changeux J-P (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88-118.
120. Narlawar R, Lane JR, Doddareddy M, Lin J, Brussee J, and Ijzerman AP (2010) Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem 53: 3028-3037.
121. Nawaratne V, Leach K, Felder CC, Sexton PM, and Christopoulos A (2010) Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285:19012-19021.
122. Neubig RR, Spedding M, Kenakin T, and Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
123. Nussinov R and Tsai CJ (2013) Allostery in disease and in drug discovery. Cell 153: 293-305.
124. Olsen RW, Chang CS, Li G, Hanchar HJ, and Wallner M (2004) Fishing for allosteric sites on GABA(A) receptors. Biochem Pharmacol 68:1675-1684.
125. Onaran HO and Costa T (2012) Where have all the active receptor states gone? Nat Chem Biol 8:674-677.
126. Overington JP, Al-Lazikani B, and Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993-996.
127. Pamplona FA, Ferreira J, Menezes de Lima O, Jr, Duarte FS, Bento AF, Forner S, Villarinho JG, Bellocchio L, Wotjak CT, and Lerner R et al. (2012) Antiinflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci USA 109:21134-21139.
128. Parmentier-Batteur S, Hutson PH, Menzel K, Uslaner JM, Mattson BA, O'Brien JA, Magliaro BC, Forest T, Stump CA, and Tynebor RM et al. (2014) Mechanism based neurotoxicity of mGlu5 positive allosteric modulators-development challenges for a promising novel antipsychotic target. Neuropharmacology 82:161-173.
129. Pasternak GW, Snowman AM, and Snyder SH (1975) Selective enhancement of [3H]opiate agonist binding by divalent cations. Mol Pharmacol 11:735-744.
130. Pert CB, Pasternak G, and Snyder SH (1973) Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182:1359-1361.
131. Potter RM, Harikumar KG, Wu SV, and Miller LJ (2012) Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J Lipid Res 53: 137-148.
132. Prasad R, Paila YD, and Chattopadhyay A (2009) Membrane cholesterol depletion enhances ligand binding function of human serotonin1A receptors in neuronal cells. Biochem Biophys Res Commun 390:93-96.
133. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, and Walker G et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495.
134. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, Violin JD, and Lefkowitz RJ (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80:367-377.
135. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D et al. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477:549-555.
136. Reiter E, Ahn S, Shukla AK, and Lefkowitz RJ (2012) Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52:179-197.
137. Rodriguez FD, Bardaji E, and Traynor JR (1992) Differential effects of Mg2+ and other divalent cations on the binding of tritiated opioid ligands. J Neurochem 59: 467-472.
138. Rominger CM, Bee WL, Copeland RA, Davenport EA, Gilmartin A, Gontarek R, Hornberger KR, Kallal LA, Lai Z, and Lawrie K et al. (2009) Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharmacol Exp Ther 329:995-1005.
139. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, and Sunahara RK et al. (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 469:236-240.
140. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
141. Rousselle JC, Massot O, Delepierre M, Zifa E, Rousseau B, and Fillion G (1996) Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes. J Biol Chem 271:726-735.
142. Schetz JA and Sibley DR (1997) Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. J Neurochem 68:1990-1997.
143. Schetz JA and Sibley DR (2001) The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J Pharmacol Exp Ther 296:359-363.
144. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, and Watson ML et al. (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29: 14271-14286.
145. Shonberg J, Herenbrink CK, López L, Christopoulos A, Scammells PJ, Capuano B, and Lane JR (2013) A structure-activity analysis of biased agonism at the dopamine D2 receptor. J Med Chem 56:9199-9221.
146. Shonberg J, Lopez L, Scammells PJ, Christopoulos A, Capuano B, and Lane JR (2014) Biased agonism at G protein-coupled receptors: the promise and the challenges-a medicinal chemistry perspective. Med Res Rev DOI: 10.1002/med.21318 [published ahead of print].
147. Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, and Zazzeroni F et al. (2010) The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Mol Pharmacol 78:925-934.
148. Simon EJ and Groth J (1975) Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions. Proc Natl Acad Sci USA 72:2404-2407.
149. Smith NJ and Milligan G (2010) Allostery at G protein-coupled receptor homo-and heteromers: uncharted pharmacological landscapes. Pharmacol Rev 62:701-725.
150. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, and Webster LR (2014) Biased agonism of the m-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain DOI:10.1016/j.pain.2014.06.011 [published ahead of print].
151. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, and Brann MR (2002) Discovery of an ectopic activation site on the M (1) muscarinic receptor. Mol Pharmacol 61:1297-1302.
152. Spedding M, Kenny B, and Chatelain P (1995) New drug binding sites in Ca2+ channels. Trends Pharmacol Sci 16:139-142.
153. Spedding M and Mir AK (1987) Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand. Br J Pharmacol 92:457-468.
154. Stallaert W, Christopoulos A, and Bouvier M (2011) Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov 6:811-825.
155. Steinfeld T, Mammen M, Smith JA, Wilson RD, and Jasper JR (2007) A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 72:291-302.
156. Sterin-Borda L, Gorelik G, PostanM, Gonzalez Cappa S, and Borda E (1999) Alterations in cardiac beta-adrenergic receptors in chagasic mice and their association with circulating beta-adrenoceptor-related autoantibodies. Cardiovasc Res 41:116-125.
157. Stewart GD, Sexton PM, and Christopoulos A (2010) Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. Mol Pharmacol 78:205-214.
158. Stockton JM, Birdsall NJM, Burgen ASV, and Hulme EC (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23: 551-557.
159. Suratman S, Leach K, Sexton P, Felder C, Loiacono R, and Christopoulos A (2011) Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 162:1659-1670.
160. Swaminath G, Lee TW, and Kobilka B (2003) Identification of an allosteric binding site for Zn2+ on the β2 adrenergic receptor. J Biol Chem 278:352-356.
161. Swaminath G, Steenhuis J, Kobilka B, and Lee TW (2002) Allosteric modulation of β2-adrenergic receptor by Zn(2+). Mol Pharmacol 61:65-72.
162. Szabo M, Klein Herenbrink C, Christopoulos A, Lane JR, and Capuano B (2014) Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D2 receptor. J Med Chem 57:4924-4939.
163. Taly A, Corringer PJ, Guedin D, Lestage P, and Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733-750.
164. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, and Li J et al. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387-1390.
165. Thomas EA, Carson MJ, Neal MJ, and Sutcliffe JG (1997) Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA 94:14115-14119.
166. Thomas EA, Carson MJ, and Sutcliffe JG (1998) Oleamide-induced modulation of 5-hydroxytryptamine receptor-mediated signaling. Ann N Y Acad Sci 861:183-189.
167. Thompson MD, Percy ME, McIntyre Burnham W, and Cole DE (2008) G proteincoupled receptors disrupted in human genetic disease. Methods Mol Biol 448: 109-137.
168. Tränkle C, Mies-Klomfass E, Cid MHB, Holzgrabe U, and Mohr K (1998) Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors. Mol Pharmacol 54:139-145.
169. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405-496.
170. Tschammer N, Bollinger S, Kenakin T, and Gmeiner P (2011a) Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol 79:575-585.
171. Tschammer N, Elsner J, Goetz A, Ehrlich K, Schuster S, Ruberg M, Kühhorn J, Thompson D, Whistler J, and Hübner H et al. (2011b) Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. J Med Chem 54:2477-2491.
172. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, and Sexton PM et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
173. Valant C, Aurelio L, Devine SM, Ashton TD, White JM, Sexton PM, Christopoulos A, and Scammells PJ (2012a) Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. J Med Chem 55:2367-2375.
174. Valant C, Aurelio L, Urmaliya VB,White P, Scammells PJ, Sexton PM, and Christopoulos A (2010) Delineating the mode of action of adenosine A1 receptor allosteric modulators. Mol Pharmacol 78:444-455.
175. Valant C, Felder CC, Sexton PM, and Christopoulos A (2012b) Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Mol Pharmacol 81: 41-52.
176. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283:29312-29321.
177. Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM, Scammells PJ, and Christopoulos A (2014) Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci USA 111:4614-4619.
178. Valant C, Robert Lane J, Sexton PM, and Christopoulos A (2012c) The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 52:153-178.
179. Valant C, Sexton PM, and Christopoulos A (2009) Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv 9:125-135.
180. Vallée M, Vitiello S, Bellocchio L, Hébert-Chatelain E, Monlezun S, Martin-Garcia E, Kasanetz F, Baillie GL, Panin F, and Cathala A et al. (2014) Pregnenolone can protect the brain from cannabis intoxication. Science 343:94-98.
181. van der Westhuizen ET, Breton B, Christopoulos A, and Bouvier M (2014) Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 85:492-509.
182. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, and Allgeier H et al. (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181.
183. Verbout NG, Lorton JK, Jacoby DB, and Fryer AD (2007) Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 292: L1126-L1135.
184. Violin JD, Crombie AL, Soergel DG, and Lark MW (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 35: 308-316.
185. Wang C, Wu H, Evron T, Vardy E, Han GW, Huang XP, Hufeisen SJ, Mangano TJ, Urban DJ, Katritch V, Cherezov V, Caron MG, Roth BL, and Stevens RC (2014) Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs. Nature Comm 5:4355.
186. Wenthur CJ, Gentry PR, Mathews TP, and Lindsley CW (2014) Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol 54:165-184.
187. Williams LT, Mullikin D, and Lefkowitz RJ (1978) Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors. J Biol Chem 253: 2984-2989.
188. Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630-644.
189. Wootten D, Savage EE, Valant C, May LT, Sloop KW, Ficorilli J, Showalter AD, Willard FS, Christopoulos A, and Sexton PM (2012) Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol Pharmacol 82:281-290.
190. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, and Cherezov V et al. (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344:58-64.
191. Zhang Y, Rodriguez AL, and Conn PJ (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 315:1212-1219.